FDA Approves Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 Vaccine
Pfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read morePfizer and BioNTech have announced that the U.S. Food and Drug Administration (FDA) has approved their supplemental Biologics License Application
Read moreNovel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read moreimusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read moreimusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read morePfizer has announced encouraging findings from its ongoing pivotal Phase 3 clinical trial, known as MONeT (RSV IMmunizatiON Study for
Read moreThe cutting-edge Dynamic Light Scattering (DLS) Particle Size Analyzer is a powerful benchtop device that enables precise particle size determination in
Read moreModerna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
Read moreGERBU’s Ready-to-use Immunoadjuvants are Economical and Animal Friendly A GERBU Biotechnik .pdf Brochure The unique GERBU Adjuvant PluS, Adjuvant S,
Read moreThe opening of Catalent’s new ultra-modern, commercial-scale plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium was announced on the 26th
Read moreModerna Inc will make investments in mRNA research and development (R&D) in the UK and construct a cutting-edge facility for
Read more